FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.
|Articles|February 20, 2009
Video: A Pharmacy for Kids
Author(s)Contemporary Pediatrics Staff
There are more than 50 million children in the US, most of whom receive some sort of medication during their childhood. That may be one reason niche pharmacies are becoming more popular.
Advertisement
Advertisement
Related to this article
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
Starting HPV vaccination earlier gives pediatricians more opportunities to protect children
3
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
4
Gut Microbiome, Immune Programming, and Allergic Disease Risk
5